Exenatide

moderate risk

Also: Byetta · Bydureon BCise · Exendin-4

Strong Evidence FDA Approved

Exenatide (Exendin-4) was the first FDA-approved GLP-1 receptor agonist, derived from Gila monster venom (Heloderma suspectum). 53% sequence homology with human GLP-1 leads to higher immunogenicity than later agents. Historically significant; clinically superseded.

Molecular Weight

4186.6 Da

Formula

C184H282N50O60S

Common Dosing

5–10 mcg SC twice daily (Byetta) or 2 mg/week SC (Bydureon)

Reported Benefits

Glycemic control

Strong Evidence 112 studies

HbA1c reduction 0.8–1.1%; FDA approved since 2005.

Weight loss

Moderate Evidence 67 studies

~3–4% weight loss — less than all subsequent GLP-1 agents.

Mechanism of Action

GLP-1 receptor partial agonist; DPP-4 resistant; stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.

Key Clinical Studies

DeFronzo et al. (2005)

Phase III RCT · n=733

PubMed →

HbA1c -0.9% at 30 weeks; first GLP-1 agonist FDA approval

Historical Importance

Exenatide proved the GLP-1 receptor agonist class in humans. The Gila monster origin story remains memorable. It has been superseded in efficacy by every subsequent GLP-1 agent, but biosimilars are making it relevant again as a cost-effective alternative.

✦ Sponsored

Stop Guessing About Your Health. Start Optimizing It.

Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.

Learn More →

Regulatory Status

FDA Approved

FDA approved — Byetta (twice daily), Bydureon (weekly ER)

Safety Profile

Side Effects

•Nausea
•Vomiting
•Immunogenicity
•Pancreatitis (rare)
•Injection site nodules (Bydureon)

Contraindications

•T1D
•Severe renal impairment
•MTC/MEN2 history

Drug Interactions

•Warfarin
•Sulfonylureas
•Oral medications

Primary Uses

Type 2 diabetesWeight loss

Related Peptides

Semaglutide Liraglutide Tirzepatide

Used For

›Obesity & Weight Loss

Planning a protocol?

Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.

Stack Builder → Protocol Builder →

Weekly Briefing

Regulatory updates + new study breakdowns.

› FDA-Approved Peptides: The Complete List (2026) › The Complete GLP-1 Class Comparison: Semaglutide vs. Tirzepatide vs. Retatrutide vs. CagriSema

For Practitioners

Do you prescribe Exenatide?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →

Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.